NUP98-HOXD13 Gene Fusion in Therapy-related Acute Myelogenous Leukemia

SZ Raza-Egilmez, SN Jani-Sait, M Grossi, MJ Higgins… - Cancer research, 1998 - AACR
SZ Raza-Egilmez, SN Jani-Sait, M Grossi, MJ Higgins, TB Shows, PD Aplan
Cancer research, 1998AACR
A novel chromosomal translocation, t (2; 11)(q31; p15), was identified in a patient with
therapy-related acute myelogenous leukemia (t-AML). Fluorescence in situ hybridization
experiments mapped the breakpoint near NUP98; Southern blot analysis demonstrated that
the nucleoporin gene NUP98 was disrupted by this translocation. We used rapid
amplification of cDNA ends to identify a chimeric mRNA. An in-frame, chimeric mRNA that
fused NUP98 sequences to the homeobox gene HOXD13 was cloned; the predicted fusion …
Abstract
A novel chromosomal translocation, t(2;11)(q31;p15), was identified in a patient with therapy-related acute myelogenous leukemia (t-AML). Fluorescence in situ hybridization experiments mapped the breakpoint near NUP98; Southern blot analysis demonstrated that the nucleoporin gene NUP98 was disrupted by this translocation. We used rapid amplification of cDNA ends to identify a chimeric mRNA. An in-frame, chimeric mRNA that fused NUP98 sequences to the homeobox gene HOXD13 was cloned; the predicted fusion protein contains both the GLFG repeats from NUP98 as well as the homeodomain from HOXD13. The NUP98-HOXD13 fusion is structurally similar to the NUP98-HOXA9 fusion previously identified in patients with AML, leading to the speculation that NUP98-homeobox gene fusions may be oncogenic. Moreover, this report, along with a recent study that demonstrated NUP98-DDX10 fusions in patients with t-AML, raises the possibility that NUP98 may be a previously unsuspected target for chromosomal translocations in patients with t-AML.
AACR